EHA 2024: Updates in the Treatment of CLL
June 27th 2024Catherine C. Coombs, MD, Matthew S. Davids, MD, MMSc; Richardo D. Parrondo, MD; Nicole Lamanna, MD, and Alexey Danilov, MD, PhD, examine treatment approaches for newly diagnosed chronic lymphocytic leukemia (CLL), including BTK inhibitor therapy, management of adverse events, and strategies for relapsed/refractory CLL.
Evolving Treatments of Metastatic CRC: Insights from ASCO 2024
June 25th 2024John Marshall, MD; Al B. Benson III, MD, FACP, FACCC, FASCO; Kristen Ciombor, MD, MSCI; Stacey Cohen, MD, and Marwan Fakih, MD, examine the landscape of second-line and third-line treatments for metastatic colorectal cancer, along with recent advancements in managing the disease.
Lower-Risk Myelodysplastic Syndromes (LR-MDS): Highlights from EHA 2024
June 24th 2024Guillermo Garcia-Manero, MD; Rami Komrokji, MD; Esther Natalie Oliva, MD; Amer Zeidan, MBBS, MHS, and Dr Thomas Cluzeauprovide expert insights on the latest developments in Lower-Risk Myelodysplastic Syndromes (LR-MDS) as presented at the European Hematology Association (EHA) 2024 conference.
ASCO 2024: Updates in the Treatment of Advanced Renal Cell Carcinoma
June 21st 2024A panel of medical experts reviews the latest advances in managing and treating renal cell carcinoma (RCC) and non-clear cell renal cell carcinoma (nccRCC), discussing recent trial data and sharing insights from their clinical practices.
Targeting NSCLC with Precision: Evaluation of the Emerging Role of Antibody-Drug Conjugates
June 21st 2024Mark Socinski, MD; Helena A. Yu, MD; Zosia Piotrowska, MD, MHS; Julia Rotow, MD, and Benjamin Levy, MD,discuss the current standard of care, emerging data on novel therapies such as antibody-drug conjugates (ADCs) and clinical trials, patient selection considerations, and practical guidance foroptimizing patient care.
Utilizing Different Mechanisms of Action for Treatment of Chronic Graft-Versus-Host Disease
January 9th 2024Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz discuss current and emerging treatment landscape of chronic graft-versus-host disease (GVHD). They examine treatment selection in different lines of therapies and the near future landscape of treatment when newer mechanisms of action become available for GVHD.